[Skip navigation] FDA Logo links to FDA home page
Center for Drug Evaluation and Research, U.S. Food and Drug AdministrationU.S. Food and Drug AdministrationCenter for Drug Evaluation and Research
  HHS Logo links to Department of Health and Human Services website

FDA Home Page | CDER Home Page | CDER Site Info | Contact CDER | What's New @ CDER

horizonal rule
CDER Home About CDER Drug Information Regulatory Guidance CDER Calendar Specific Audiences CDER Archives
 
Powered by Google
 

Warning Letters and Untitled Letters
to Pharmaceutical Companies
2004

These letters, sorted by month, are supplied by the CDER Freedom of Electronic Information Office. This page only covers Division of Drug Marketing and Communications and Headquarters Warning Letters.  For District Office Warning Letters see the Main FDA FOI Warning Letters Page.    Some of the letters have been redacted or edited to remove confidential information. Click on the month to view the letters in Adobe Acrobat format.

Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the recipient of the letter that may have changed the regulatory status of the issues discussed in the letter.  If you wish to obtain available additional information on the current status of an issue in a particular warning letter or notice of violation on this website, please contact the Agency or the recipient of the letter directly.  Inquiries to FDA should be sent to: Food and Drug Administration, Freedom of Information Staff (HFI-35), 5600 Fishers Lane, Rockville, MD 20857. Instructions for how to submit an FOI request can be found on the FDA FOI Page.

The letters are arranged in chronological order by month.  Click on the month to view the letters in Adobe Acrobat (PDF) format. Go here for further information about Adobe Acrobat and download instructions.

Also see the "Cyber" Letters.

2004 [2003] [2002] [2001] [2000] [1999] [1998] [1997]

November 2004

Product/Issue Company Division Released Posted
Pamine (methscopolamine bromide) (Warning Letter) Bradley Pharmaceuticals DDMAC 11/9/2004 11/17/2004
Tramadol hydrochloride tablets Mallinckrodt, Inc. DDMAC 11/1/2004 11/15/2004
Viagra (sildenafil citrate) Tablets Pfizer DDMAC 11/10/2004 11/15/2004

October 2004

Product/Issue Company Division Released Posted
Kaletra (lopinavir/ritonavir) Capsules and Oral Suspension Abbott Laboratories DDMAC 10/29/2004 11/2/2004

September 2004

Product/Issue Company Division Released Posted
Atrovent (ipratropium bromide) Inhalation Aerosol and Combivent (ipratropium bromide and albuterol sulfate) Inhalation Aerosol (Warning Leter) Boehringer Ingelheim Pharmaceuticals, Inc. DDMAC 9/23/2004 9/24/2004

Duragesic (fentanyl transdermal system) (Warning Letter)

Janssen Pharmaceutica

DDMAC 9/3/2004 9/16/2004
Topamax (topiramate) Tablets and Topamax (topiramate capsules) Sprinkles (Warning Letter) Ortho-McNeil Pharmaceutical, Inc DDMAC 9/15/2004 9/22/2004
Viadur (leuprolide acetate implant) (Warning Letter) Alza Corporation DDMAC 9/21/2004 9/28/2004
Viramune (nevirapine) Tablets and Viramune (nevirapine) Oral Suspension Boehringer Ingelheim Pharmaceuticals, Inc. DDMAC 9/22/2004 9/22/2004

August 2004

Product/Issue Company Division Released Posted

Cubicin (daptomycin for injection) (Warning Letter)

Cubist Pharmaceuticals

DDMAC 8/17/2004 8/24/2004
Site Inspection (Warning Letter) Bigmar-Bioren SA Compliance 8/3/2004 8/6/2004

June 2004

Product/Issue Company Division Released Posted
Domperidone (Warning Letter) Axium Healthcare Pharmacy Compliance 6/7/2004 6/7/2004
Domperidone (Warning Letter) Drugs Are Us, Inc. DBA Hopewell Pharmacy Compliance 6/7/2004 6/7/2004
Domperidone (Warning Letter) Peoples Pharmacy, Inc. Compliance 6/7/2004 6/7/2004
Domperidone (Warning Letter) Spectrum Chemicals & Laboratory Products Compliance 6/7/2004 6/7/2004
Domperidone Line Avenue Pharmacy Compliance 6/7/2004 6/7/2004
Norvir (ritonavir capsules) (Warning Letter) Abbot Laboratories DDMAC 6/10/2004 6/10/2004
Paxil CR (paroxetine HCl) GlaxoSmithKline DDMAC 6/2004 6/10/2004

May 2004

Product/Issue Company Division Released Posted
MUSE (alprostadil) (Warning Letter) VIVUS, Inc. DDMAC 5/25/2004 5/27/2004
Prograf. (tacrolimus) (Warning Letter) Fujisawa Healthcare, Inc. DDMAC 5/7/2004 5/13/2004

April 2004

Product/Issue Company Division Released Posted
Diovan (Valsartan) (Warning Letter) Novartis DDMAC 4/21/2004 4/29/2004
Facility Inspection MDS Pharma Services DSI 4/26/2004 5/7/2004
Risperdal (risperidone) (Warning Letter) Janssen DDMAC 4/19/2004 4/29/2004
Zyrtec-D 12 Hour Pfizer DDMAC 4/22/2004 4/29/2004

March 2004

Product/Issue Company Division Released Posted
Effexor, Effexor XR Wyeth Pharmaceuticals DDMAC 3/18/2004 2/26/2004

February 2004

Product/Issue Company Division Released Posted
Bexxar (tositumomab and iodine I 131 tositumomab) (Warning Letter Corixa Corporation DDMAC 3/16/2004 3/19/2004
Facility Inspection (Warning Letter) Shanghai Medical, Ltd. DMPQ 2/10/2004 2/27/2004
Prescription Drug Importation

(Warning Letter)

Discount Prescriptions from Canada, Inc. Compliance 2/18/2004 2/19/2004

January 2004

Product/Issue Company Division Released Posted
API Site Inspection (Warning Letter) Delta Synthetic Co. Compliance 1/5/2004 5/19/2004
API Site Inspection (Warning Letter) Aliachem A.S. Compliance 1/15/2004 5/19/2004
Prescription Drug Importation

(Warning Letter)

  • Expedite-RX
  • SPC Global Technologies, Ltd.
  • Employer Health Options, Inc.
Compliance 1/22/2004 1/23/2004

Back to Top     Index

Date created: January 23, 2004; updated November 17, 2004

horizonal rule